CDKN1A and glioma: In this study, we focused on Cell Cycle Protein Dependent Kinase Inhibitor 1A (CDKN1A), which is a regulator of the E2F1 transcription factor and may play a key role in DDR‐related signaling pathways in gliomas and influence TMZ resistance.